Loading
PDBj
MenuPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

7JY4

hALK in complex with ((1S,2S)-1-(2,4-difluorophenyl)-2-(2-(3-methyl-1H-pyrazol-5-yl)-4-(trifluoromethyl)phenoxy)cyclopropyl)methanamine

Summary for 7JY4
Entry DOI10.2210/pdb7jy4/pdb
DescriptorALK tyrosine kinase receptor, 1-{(1S,2S)-1-(2,4-difluorophenyl)-2-[2-(3-methyl-1H-pyrazol-5-yl)-4-(trifluoromethyl)phenoxy]cyclopropyl}methanamine (3 entities in total)
Functional Keywordsalk tyrosine kinase receptor, inhibitor, complex, kinase, sbdd, transferase-inhibitor complex, transferase
Biological sourceHomo sapiens (Human)
Total number of polymer chains1
Total formula weight36892.13
Authors
McGrath, A.P.,Zou, H.,Lane, W.,Saikatendu, K. (deposition date: 2020-08-28, release date: 2021-01-20, Last modification date: 2023-10-18)
Primary citationFujimori, I.,Wakabayashi, T.,Murakami, M.,Okabe, A.,Ishii, T.,McGrath, A.,Zou, H.,Saikatendu, K.S.,Imoto, H.
Discovery of Novel and Highly Selective Cyclopropane ALK Inhibitors through a Fragment-Assisted, Structure-Based Drug Design.
Acs Omega, 5:31984-32001, 2020
Cited by
PubMed Abstract: Fragment screening is frequently used for hit identification. However, there was no report starting from a small fragment for the development of an anaplastic lymphoma kinase (ALK) inhibitor, despite the number of ALK inhibitors reported. We began our research with the fragment hit and our subsequent linker design, and its docking analysis yielded novel -1,2,2-trisubstituted cyclopropane . The fragment information was integrated with a structure-based approach to improve upon the selectivity over tropomyosin receptor kinase A, leading to the potent and highly selective ALK inhibitor, 4-trifluoromethylphenoxy--1,2,2-trisubstituted cyclopropane . This work shows that fragments become a powerful tool for both lead generation and optimization, such as the improvement of selectivity, by combining them with a structure-based drug design approach, resulting in the fast and efficient development of a novel, potent, and highly selective compound.
PubMed: 33344853
DOI: 10.1021/acsomega.0c04900
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.42 Å)
Structure validation

226707

數據於2024-10-30公開中

PDB statisticsPDBj update infoContact PDBjnumon